Mirikizumab for Crohn's disease

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [21] Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease
    Magro, F.
    De Hertogh, G.
    Protic, M.
    Chan, L. S.
    Pollack, P.
    Feagan, B. G.
    Harpaz, N.
    Pai, R.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I129 - I130
  • [22] EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
    Sands, Bruce E.
    Sandborn, William J.
    Peyrin-Biroulet, Laurent
    Higgins, Peter D.
    Hirai, Fumihito
    Jairath, Vipul
    D'Haens, Geert
    Abreu, Maria T.
    Belin, Ruth
    Valderas, Elisa Gomez
    Miller, Debra
    Naegeli, April N.
    Arora, Vipin
    Pollack, Paul
    Tuttle, Jay
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2021, 160 (06) : S37 - S37
  • [23] Exit interviews exploring Crohn's disease patients' experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease
    Gibble, T. H.
    Macey, J.
    Makin, H.
    Rosu, R.
    Mellor, K.
    Kitchen, H.
    Carlier, H.
    Dubinsky, M. C.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1343 - I1344
  • [24] Extraintestinal Crohn's disease (metastatic Crohn's disease)
    Rozalski, Michal
    PRZEGLAD DERMATOLOGICZNY, 2014, 101 (05): : 418 - 422
  • [25] When is Crohn"s disease Crohn's disease? Comment
    Sachdev, R
    Cave, DR
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 63 - 63
  • [26] De novo Crohn's disease in AIDS: Crohn's disease or Crohn's "syndrome"?
    Yoshida, EM
    Owen, DA
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1998, 26 (01) : 93 - 93
  • [27] Crohn's disease or Crohn's diseases?
    Arnott, IDR
    Satsangi, J
    GUT, 2003, 52 (04) : 460 - 461
  • [28] Improvement in fatigue with mirikizumab therapy is associated with improvements in patient-reported outcomes in patients with moderately to severely active Crohn's disease
    Reguiero, Miguel
    Fischer, Monika
    Rubin, David T.
    Hibi, Toshifumi
    Bossuyt, Peter
    Juillerat, Pascal
    Pollack, Paul
    Zhou, Xian
    Protic, Marijana
    Hunter, Theresa
    Chan, Lai Shan
    Carlier, Hilde
    Hindryckx, Pieter
    SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 27S
  • [29] Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104
    Regueiro, Miguel
    Fischer, Monika
    Bossuyt, Peter
    McGinnis, Kim
    Gibble, Theresa Hunter
    Protic, Marijana
    Panni, Tommaso
    Hibi, Toshifumi
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S816
  • [30] Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
    Pai, R.
    De Hertogh, G.
    Reinisch, W.
    Harpaz, N.
    Feagan, R.
    Agada, N.
    Pollack, P.
    Chan, L. S.
    Protic, M.
    Magro, F.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S404 - S406
12345